Caribou Biosciences, Inc. announced the appointment of Syed Rizvi, M.D., to the newly created position of chief medical officer. Dr. Rizvi has more than two decades of experience in all stages of drug development, from clinical strategy and execution through regulatory submissions to support approval and commercialization of several cancer treatments, including two autologous CAR-T cell therapies ABECMA® and BREYANZI®. Dr. Rizvi most recently served as chief medical officer of Chimeric Therapeutics, where he led the strategy and execution of clinical development programs for the company's T cell and NK cell therapy platforms and helped build the pipeline.